(Alliance News) - Angle PLC on Wednesday noted positive results from a study of its Parsortix system in small cell lung cancer.Parsortix is Angle's liquid biopsy technology, meaning it Read More
(Alliance News) - Liquid biopsy firm Angle PLC said Thursday the first patients for its ovarian cancer test study have been enrolled ahead of anticipated completion early in 2020.The study Read More
(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done to develop a "robust, reliable and for of Read More
(Alliance News) - Angle PLC on Friday said its Parsortix system has been successfully used as a liquid biopsy to investigate an immunotherapy target in lung cancer.Shares in Angle were up a Read More
LONDON (Alliance News) - Angle PLC on Wednesday announced positive results from a study evaluating the ability of its Parsortix and HyCEAD Ziplex platforms to test for ovarian cancer.The to Read More
LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said its Parsortix system has been used in "groundbreaking" cancer research.The research showed the first the time Read More
LONDON (Alliance News) - Angle PLC on Thursday said its ParsortixTM system was used by the University of Texas MD Anderson Cancer Center to develop a new technique for assessing the metastatic of Read More
